Novel Triple Immunotherapy Combo Rekindles Hope for Pancreatic Cancer Patients
Pancreatic cancer is the third-leading cause of cancer-related deaths in the US. Despite mammoth advancements in improving chemotherapeutic regimens, metastatic pancreatic adenocarcinomas still pose a greater clinical challenge due to dismal prognosis. However, MIT researchers now develop a novel triple immunotherapy combo that could potentially shrink or even eliminate pancreatic tumors.
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
New York city,USA
3rd INTERNATIONAL CONFERENCE ON NUTRITION AND HEALTHCARE